Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Inhibikase Therapeutics Inc
(NQ:
IKT
)
2.040
-0.060 (-2.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
52,727
Open
2.120
Bid (Size)
1.820 (2)
Ask (Size)
2.000 (50)
Prev. Close
2.100
Today's Range
2.020 - 2.130
52wk Range
0.7900 - 4.181
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
April 18, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
April 03, 2024
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension
From
Inhibikase Therapeutics
Via
GlobeNewswire
Performance
YTD
+53.18%
+53.18%
1 Month
+5.70%
+5.70%
3 Month
+17.24%
+17.24%
6 Month
+119.35%
+119.35%
1 Year
-40.97%
-40.97%
More News
Read More
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023
March 27, 2024
Via
InvestorPlace
Inhibikase Therapeutics: Q3 Earnings Insights
November 14, 2023
Via
Benzinga
Earnings Preview For Inhibikase Therapeutics
November 13, 2023
Via
Benzinga
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
March 27, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 07, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
March 05, 2024
Via
Benzinga
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
February 28, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
February 07, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
February 05, 2024
Via
NewMediaWire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via
AB Newswire
Topics
Retirement
Exposures
Pension
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
January 29, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
January 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
January 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 24, 2024
Via
Benzinga
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
January 16, 2024
From
Inhibikase Therapeutics
Via
GlobeNewswire
Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
January 05, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
December 19, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 13, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 12, 2023
Via
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 04, 2023
Via
Benzinga
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
December 04, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
November 14, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.